[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Duvic M, Foss FM: Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol; 2007 Dec;34(6 Suppl 5):S21-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycosis fungoides: pathophysiology and emerging therapies.
  • Mycosis fungoides and its leukemic variant Sézary syndrome represent the most common CTCL subtypes.
  • Current treatment for patients with mycosis fungoides involves topical and systemic therapies for the cutaneous manifestations.
  • However, no therapy is curative and patients often progress to advanced extracutaneous CTCL with visceral organ complications or relapsed disease that is frequently refractory to most topical and aggressive systemic regimens.
  • The emergence of novel targeted therapies such as biologic agents, histone deacetylase inhibitors, and purine nucleoside phosphorylase inhibitors offers promise for more effective and safer treatment strategies for refractory CTCLs.
  • [MeSH-major] Histone Deacetylases / drug effects. Mycosis Fungoides. Purine-Nucleoside Phosphorylase / drug effects. Skin Neoplasms
  • [MeSH-minor] Clinical Trials as Topic. Humans. Immunologic Factors / therapeutic use. Purine Nucleosides / therapeutic use. Pyrimidinones / therapeutic use. Sezary Syndrome / drug therapy. Sezary Syndrome / physiopathology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086343.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 56
  •  go-up   go-down


2. Khaled A, Fazaa B, Goucha S, Zeglaoui F, Kamoun MR: PUVA therapy and narrowband UVB therapy in Tunisian patients with mycosis fungoides. Therapie; 2009 Nov-Dec;64(6):389-94
Genetic Alliance. consumer health - Mycosis fungoides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PUVA therapy and narrowband UVB therapy in Tunisian patients with mycosis fungoides.
  • BACKGROUND: PUVA therapy and narrowband UVB therapy (NBUVB) constitute a widely used first line therapy in mycosis fungoides (MF).
  • One patient had both treatments (PUVA then NBUVB for a relapse).
  • Both had relapsed after 40 sessions and 7 months later, respectively.
  • Relapses were treated by PUVA maintenance treatment (2 sessions/2 weeks) and NBUVB leading to CR.
  • PUVA therapy is effective even on infiltrated plaques.
  • Both treatments do not prevent relapses.
  • [MeSH-major] Mycosis Fungoides / drug therapy. Mycosis Fungoides / radiotherapy. PUVA Therapy. Ultraviolet Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025842.001).
  • [ISSN] 0040-5957
  • [Journal-full-title] Thérapie
  • [ISO-abbreviation] Therapie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Tsuji H, Wada T, Murakami M, Kashiwagi T, Ito Y, Ishida-Yamamoto A, Jimbo J, Shindo M, Sato K, Kohgo Y, Iizuka H: Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. J Dermatol; 2010 Dec;37(12):1040-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation.
  • Mycosis fungoides is a cutaneous T-cell lymphoma, which is clinically divided into three stages: patch, plaque and tumor.
  • Despite a variety of treatments the prognosis is poor in advanced mycosis fungoides.
  • We performed reduced-intensity umbilical cord blood transplantation for two advanced mycosis fungoides patients.
  • Tumors of each case were refractory to conventional chemotherapy.
  • Although radiation therapy was considerably effective, tumors relapsed after several months.
  • However, chemotherapy-resistant tumors relapsed, and allogeneic hematopoietic stem cell transplantation was performed at 17 months.
  • She died of cerebral hemorrhage 23 days after the procedure.
  • Reduced-intensity umbilical cord blood transplantation may be included in the treatments for advanced mycosis fungoides, where graft-versus-lymphoma effect seems to be a significant factor for the success of the treatment.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Mycosis Fungoides / surgery. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Dermatological Association.
  • (PMID = 21083707.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Ishida M, Hotta M, Takikita-Suzuki M, Kojima F, Okabe H: CD8-positive granulomatous mycosis fungoides: a case report with review of the literature. J Cutan Pathol; 2010 Oct;37(10):1072-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD8-positive granulomatous mycosis fungoides: a case report with review of the literature.
  • Granulomatous mycosis fungoides (GMF) represents an uncommon variant of mycosis fungoides (MF) characterized by the presence of an associated granulomatous reaction.
  • She had been diagnosed with MF, and most of the eruption improved by psoralen ultraviolet A therapy.
  • However, the eruption relapsed and gradually expanded 5 months prior to her visit to our hospital.
  • [MeSH-major] Antigens, CD8 / biosynthesis. Granuloma / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diabetes Mellitus / pathology. Female. Humans. Immunohistochemistry. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. PUVA Therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20579213.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD8
  •  go-up   go-down


5. Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P, Mesina O, King K, Medeiros LJ, Rassidakis GZ, Samuels B, Cabanillas F: Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol; 2002 Jun 15;20(12):2876-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimetrexate in relapsed T-cell lymphoma with skin involvement.
  • Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed relapsed T-cell lymphoma involving the skin, had received more than one previous regimen, were older than 16 years, had normal organ function, and had no CNS disease or serious infections, including human immunodeficiency virus.
  • Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sézary syndrome (14 with large-cell transformation), and two had peripheral T-cell lymphoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Lymphoma, T-Cell, Cutaneous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trimetrexate / pharmacology
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. TRIMETREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065565.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; UPN4ITI8T4 / Trimetrexate
  •  go-up   go-down


6. Bittencourt AL, Mota K, Oliveira RF, Farré L: A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol; 2009 Dec;31(8):834-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report.
  • Adult T-cell leukemia/lymphoma (ATL) is an aggressive type of leukemia/lymphoma associated with the human T-cell lymphotropic virus (HTLV-I).
  • We describe an adult male patient clinically and pathologically diagnosed as mycosis fungoides and treated with chemotherapy after which complete involution of the lesions occurred.
  • The disease relapsed with confluent dyshidrosis-like vesicles on the palmoplantar regions, followed by disseminated vesiculopapules and associated lymphocytosis.
  • A serological test performed at this time revealed HTLV-I infection, and a diagnosis of chronic ATL was made.
  • The delay that occurred in diagnosing ATL was due to the fact that mycosis fungoides and ATL may present the same clinical, histopathological, and immunohistochemical features.
  • [MeSH-major] Eczema, Dyshidrotic / pathology. HTLV-I Infections / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide. Diabetes Mellitus. Diagnosis, Differential. Doxorubicin. Human T-lymphotropic virus 1. Humans. Immunohistochemistry. Interferon-alpha / therapeutic use. Male. Polymerase Chain Reaction. Prednisone. Vincristine. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770630.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, Ryan G, Prince HM: Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol; 2003 Oct;71(4):250-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
  • OBJECTIVES: Alemtuzumab (anti-CD52, Campath-1H) has recently been shown to be effective in the treatment of a range of hematological malignancies, including B-cell chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
  • We undertook a phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T-cell lymphoma.
  • PATIENTS AND METHODS: A total of eight patients were enrolled, seven with mycosis fungoides/Sézary syndrome (MF/SS) and one with large-cell transformation of MF.
  • Seven patients had disease refractory to multiple previous therapies.
  • Alemzumab (30 mg) was administered intravenously three times per week for 12 wk or until maximum response.
  • RESULTS: The overall response rate was 38%, with three patients achieving partial remission, two patients with stable disease and three patients with progressive disease (PD) during treatment.
  • The time to progression was short, with all patients developing PD within 4 months of starting alemtuzumab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Mycosis Fungoides / drug therapy. Sezary Syndrome / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Disease Progression. Humans. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950233.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


8. Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Stratigos A, Stavrianeas N, Katsambas A: Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol; 2008;9(3):169-73
Genetic Alliance. consumer health - Mycosis fungoides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
  • Although combinations of oral bexarotene and psoralen plus UVA (PUVA) have been tried in patients with all stages of mycosis fungoides (MF), the dosage of bexarotene used in these combination regimens has been variable.
  • OBJECTIVE: To assess the efficacy and safety of low-dose oral bexarotene and PUVA in patients with relapsed or treatment-refractory MF following monotherapy with multiple agents including PUVA, narrow-band UVB, interferon-alpha, oral bexarotene, and topical corticosteroids.
  • METHOD: Combination therapy with PUVA three times weekly and low-dose oral bexarotene (150 or 300 mg/day, depending on physicians' preference) was administered to 14 patients, seven men and seven women (median age 49.5 years, range 30-75 years), with relapsed or refractory MF stages I-III.
  • All responders received maintenance treatment at the same bexarotene dose that induced remission until progression or unacceptable toxicity.
  • RESULTS: Low-dose oral bexarotene combined with PUVA was associated with an overall response rate (complete response or partial response) in 67% of the nine patients with refractory MF who completed the treatment course.
  • Oral bexarotene was continued as maintenance therapy in three of the four complete responders (one refused); two of these patients relapsed 2-10 months after PUVA discontinuation.
  • Patients with partial response or stable disease received the combination for 3-5 months and were switched to another treatment regimen because of lack of further response.
  • Therapy was fairly well tolerated.
  • CONCLUSION: In a select population of patients who had not responded to at least one monotherapy for early-stage MF, a combination of low-dose oral bexarotene and PUVA was successful in achieving a satisfactory overall response rate in 67% of patients who completed the treatment course and was fairly well tolerated.
  • [MeSH-major] Mycosis Fungoides / drug therapy. Tetrahydronaphthalenes / therapeutic use
  • [MeSH-minor] Adult. Aged. Anticarcinogenic Agents / adverse effects. Anticarcinogenic Agents / therapeutic use. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. PUVA Therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429646.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


9. Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, Kasai M, Miura I, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K, Cladribine Study Group: Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol; 2004 Oct;80(3):267-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
  • We conducted a phase II study to evaluate the efficacy and safety of cladribine (2-chlorodeoxyadenosine [2-CdA]) for patients with refractory or relapsed indolent B-cell lymphoma or mycosis fungoides.
  • Neutropenia and thrombocytopenia of grade 3 or 4 were observed in 53.3% and 37.8% of patients, respectively, with prolonged cytopenia observed in patients with increased numbers of treatment cycles.
  • Two treatment-related deaths were observed.
  • Four patients developed myelodysplastic syndrome (MDS) at 13 months to 2 years after completion of the 2-CdA treatments.
  • 2-CdA is an active agent with acceptable toxicity for refractory or relapsed indolent lymphoma; however, prolonged myelosuppression and the potential development of MDS should be carefully monitored.
  • [MeSH-major] Cladribine / administration & dosage. Cladribine / toxicity. Lymphoma, Non-Hodgkin / drug therapy. Pancytopenia / chemically induced
  • [MeSH-minor] Adult. Aged. Female. Humans. Japan. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Male. Middle Aged. Mycosis Fungoides / complications. Mycosis Fungoides / drug therapy. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced. Recurrence. Remission Induction / methods. Salvage Therapy / methods. Survival Analysis

  • Hazardous Substances Data Bank. CLADRIBINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Feb 15;85(4):1075-82 [7849295.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] Blood. 1992 Aug 1;80(3):587-92 [1353380.001]
  • [Cites] Int J Hematol. 2001 Apr;73(3):363-8 [11345204.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):918-26 [7961120.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2527-34 [7989926.001]
  • [Cites] Leuk Res. 1992;16(1):61-5 [1732675.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):99-105 [9250793.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):983-8 [7707127.001]
  • [Cites] Blood. 1988 Sep;72(3):1069-73 [2901280.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1739-46 [12175690.001]
  • [Cites] J Clin Oncol. 1985 Jun;3(6):769-75 [3839262.001]
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Blood. 1983 Oct;62(4):737-43 [6136305.001]
  • [Cites] Blood. 1992 Feb 15;79(4):882-7 [1346577.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):559-66 [8395872.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1117-21 [1969613.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):957-64 [9486587.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1462-7 [4027881.001]
  • [Cites] Eur J Haematol. 1991 Jul;47(1):17-27 [1868912.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):952-6 [1357355.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] J Clin Oncol. 1985 Mar;3(3):299-310 [3882893.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1039-45 [8388919.001]
  • [Cites] Cancer. 1978 Jan;41(1):23-8 [580070.001]
  • [Cites] Eur J Haematol. 2001 Mar;66(3):188-94 [11350487.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1215-22 [1694056.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):371-7 [1346801.001]
  • [Cites] Jpn J Cancer Res. 1994 Dec;85(12):1270-9 [7531681.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):644-51 [8478660.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):146-53 [9255268.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):139-43 [8094003.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):441-7 [3338014.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3780-6 [8204897.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Blood. 1994 May 15;83(10):2829-35 [8180379.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):788-92 [7908690.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1710-6 [7655003.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • (PMID = 15540903.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine
  •  go-up   go-down


10. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol; 2007 Sep 20;25(27):4293-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
  • RESULTS: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable.
  • Overall, the drug was well tolerated, with no grade 4 toxicity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Lymphoma, T-Cell / drug therapy. Mycosis Fungoides / drug therapy. Protease Inhibitors / pharmacology. Pyrazines / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Bortezomib. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


11. Dueck GS, Chua N, Prasad A, Stewart D, White D, vanderJagt R, Johnston JB, Belch A, Reiman T: Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol; 2009 May 20;27(15_suppl):8524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8524 Background: Novel therapies are needed to improve outcomes in T-cell lymphomas.
  • METHODS: Patients with relapsed and refractory T-cell lymphomas other than mycosis fungoides were prescribed oral lenalidomide (25mg daily) on days 1 to 21 of each 28 day cycle, with standardized dose reductions for toxicity.
  • Treatment continued until disease progression, death or unacceptable toxicity.
  • RESULTS: At the time of this interim analysis, 24 patients were enrolled in this study and 23 were evaluable for response.
  • Median number of prior therapies was 1 (range, 0-4), and three had prior autologous stem cell transplant.
  • Four patients were previously untreated and not candidates for combination chemotherapy.
  • Median time from completion of prior therapy to the start of lenalidomide was 8 months (range, 1-48 months).
  • The most common grade 3 adverse events were neutropenia (20.8%), febrile neutropenia (16.7%), and pain NOS (16.7%).
  • CONCLUSIONS: In relapsed and refractory T-cell lymphomas, oral lenalidomide monotherapy has clinical activity and toxicity is consistent with the known profile of lenalidomide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960899.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol; 2001 May;144(5):1010-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
  • BACKGROUND: The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukaemia.
  • METHODS: Nine patients with erythrodermic CTCL were identified for the study, eight of whom met the criteria for Sézary syndrome (SS), and three with tumour-stage mycosis fungoides (MF).
  • Six patients had treatment withdrawn, five due to bone marrow suppression and one due to progressive disease.
  • No difference in pretrial parameters were found in those who had treatment withdrawn and those who tolerated at least three courses.
  • As with other multiagent chemotherapy regimens, bone marrow toxicity is a common and severe side-effect.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Mycosis Fungoides / drug therapy. Pilot Projects. Sezary Syndrome / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11359390.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


13. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM: Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma; 2009 Dec;50(12):1969-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
  • We present the results of an open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) (erythrodermic mycosis fungoides and Sézary syndrome).
  • Ten patients received alemtuzumab intravenously using an escalating dose regimen with a final dose of 30 mg three times weekly for 4 weeks followed by subcutaneous administration for 8 weeks.
  • One patient was diagnosed with a concurrent lymphoma (mantle cell lymphoma) 6 months after completing alemtuzumab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Mycosis Fungoides / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Flow Cytometry. Glycoproteins / analysis. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Pruritus / chemically induced. Remission Induction. Survival Analysis. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860617.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


14. Vang R, Medeiros LJ, Malpica A, Levenback C, Deavers M: Non-Hodgkin's lymphoma involving the vulva. Int J Gynecol Pathol; 2000 Jul;19(3):236-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients had neoplasms localized to the vulva, and two patients had a history of NHL that secondarily involved the vulva; in another patient the stage was unknown, and the sixth patient had stage IVA mycosis fungoides/Sezary syndrome involving the vulva.
  • Each tumor was classified according to the revised European-American classification of lymphoid neoplasms: four were diffuse large B-cell lymphoma, one was peripheral T-cell lymphoma, and one was mycosis fungoides/Sezary syndrome.
  • Two patients were treated with chemotherapy and radiotherapy, one patient received chemotherapy and phototherapy, one patient was treated with chemotherapy, and in two patients the treatment is unknown.
  • One patient with low-stage NHL responded to therapy, but relapsed and died of disease 2 years later.
  • The patient with mycosis fungoides/Sezary syndrome is alive with disease at 4 years.
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasm Staging. Sezary Syndrome / pathology. Skin Neoplasms / pathology. Vulva / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907172.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


15. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol; 2007 Jul 20;25(21):3109-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
  • PURPOSE: To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.
  • Patients must have received at least two prior systemic therapies at least one of which included bexarotene unless intolerable.
  • The primary end point was the objective response rate (ORR) measured by the modified severity weighted assessment tool and secondary end points were time to response (TTR), time to progression (TTP), duration of response (DOR), and pruritus relief ( > or = 3-point improvement on a 10-point visual analog scale).
  • The most common drug-related adverse experiences (AE) were diarrhea (49%), fatigue (46%), nausea (43%), and anorexia (26%); most were grade 2 or lower but those grade 3 or higher included fatigue (5%), pulmonary embolism (5%), thrombocytopenia (5%), and nausea (4%).
  • CONCLUSION: Oral vorinostat was effective in treatment refractory MF/SS with an acceptable safety profile.
  • [MeSH-major] Hydroxamic Acids / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Salvage Therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Survival Analysis. Treatment Outcome


16. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol; 2010 Apr;21(4):860-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy.
  • Inclusion criteria were as follows: histologic diagnosis of MF or PTCLU; relapsed/refractory disease; age > or =18 years; and World Health Organization performance status of two or less.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887465.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol; 2000 Jul;18(13):2603-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
  • PURPOSE: To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas.
  • PATIENTS AND METHODS: Between May 1997 and February 1999, 44 previously treated patients with mycosis fungoides (MF; n = 30) and peripheral T-cell lymphoma unspecified (PTCLU) with exclusive skin involvement (n = 14) were enrolled onto a two-institution, phase II trial and treated with gemcitabine.
  • This drug was given on days 1, 8, and 15 of a 28-day schedule at a dose of 1,200 mg/m(2) intravenously over 30 minutes for a total of three courses.
  • 5%) achieved complete responses (CRs), 26 (59%) partial responses (PRs), and the remaining 13 showed no benefit from the treatment.
  • No difference in terms of overall response rate was observed between relapsed and refractory patients.
  • Treatment was well tolerated; hematologic toxicity was mild, and no nausea/vomiting or organ toxicity was recorded.
  • Further studies that use gemcitabine alone or in combination with other drugs in earlier stages of the disease are needed.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mycosis Fungoides / drug therapy. Mycosis Fungoides / mortality. Mycosis Fungoides / pathology. Survival Rate

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10893292.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Talpur R, Apisarnthanarax N, Ward S, Duvic M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma; 2002 Jan;43(1):121-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).
  • In general, their prognosis is poor, and specific therapy is not well defined.
  • We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK).
  • This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Aged. Erythema / etiology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymph Nodes / pathology. Male. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Receptors, Interleukin-2 / drug effects. Receptors, Interleukin-2 / metabolism. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908715.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21-CA74117
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


19. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM: Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol; 2004 Jul;51(1):25-32
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common subtypes of cutaneous T-cell lymphomas are the epidermotropic variants mycosis fungoides and Sézary syndrome.
  • Treatment of mycosis fungoides has encompassed a variety of modalities including the use of retinoids with several studies evaluating their efficacy.
  • The objective of our retrospective, nonrandomized, single-center study was to compare the response, survival outcomes, and toxic effects in our phase II trial of the RAR-specific retinoid, all-trans retinoic acid, with clinical use of the RXR-specific retinoid, bexarotene, in patients with mycosis fungoides/Sézary syndrome who have relapsed.
  • There was no statistical difference in response rates (12% vs 21%), response duration (20.5 vs 7.3 months), event-free survival time (4 vs 5 months), or median survival when corrected for length of follow-up.
  • Both have favorable toxicity profiles that can be managed with medications.
  • However, the immunomodulatory effects of RAR and RXR retinoids provide a rational basis for using retinoids in combination with other biologic immune response modifiers, phototherapy, or cytotoxic chemotherapy.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Receptors, Retinoic Acid. Retinoid X Receptors. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15243520.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / Tetrahydronaphthalenes; 5688UTC01R / Tretinoin; A61RXM4375 / bexarotene
  •  go-up   go-down


20. Du-Thanh A, Durand L, Costes V, Guillot B, Dereure O: [Aggressive T cytotoxic CD8+ epidermotropic cutaneous lymphoma: a case in a patient with Steinert's myotonic dystrophy]. Ann Dermatol Venereol; 2006 Dec;133(12):991-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphome T cutané épidermotrope cytotoxique CD8+ "agressif": difficultés de prise en charge chez un malade atteint d'une dystrophie myotonique de Steinert.
  • INTRODUCTION: Primary cutaneous "aggressive" CD8-positive epidermotropic cytotoxic T-cell lymphoma is a rare subset of cutaneous cytotoxic T/NK lymphomas that clearly differs from mycosis fungoides, whether CD4+ or CD8+, by the presence of rapidly evolving tumoral cutaneous lesions, foci of keratinocytes necrosis, a cytotoxic T phenotype and a poor prognosis.
  • CHOP chemotherapy was effective despite cardiac toxicity in the setting of Steinert's dystrophy, but the patient relapsed and died of pulmonary sepsis after chemotherapy was resumed.
  • DISCUSSION: The treatment of primary cutaneous epidermotropic CD8+ cytotoxic T-cell lymphoma is not codified.
  • CHOP chemotherapy is usually the first-line therapy but relapses are frequent with median survival of no more than 34 months.
  • In our patient, an additional difficulty was the cardiac toxicity of cytostatic drugs linked to the myopathy which prevented the use of high dosages, requiring a change of therapeutic regimen.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185931.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K: Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol; 2006;7(3):155-69
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mycosis fungoides is recognized as the most common type of CTCL.
  • However, although there is a wide array of therapeutic options for early-stage CTCL, not all patients respond to these individual therapies, resulting in refractory cutaneous disease over time.
  • Refractory early-stage CTCL poses an important therapeutic challenge, as one of the principal treatment goals is to keep the disease confined to the skin, thereby preventing disease progression.
  • Much of the focus of current research has been on the evaluation of already available skin-directed therapies and biologic response modifiers and combination regimens thereof, such as the combination of psoralen and UVA (PUVA) with interferon-alpha or retinoids.
  • Likewise, the topical gel formulation of bexarotene has proved to be an important therapeutic option in patients with refractory or relapsed lesions.
  • Oral bexarotene and topical bexarotene have been approved by the US FDA for the treatment of refractory CTCL.
  • Systemic chemotherapy is typically reserved for advanced-stage CTCL and is usually not recommended for early-stage, skin-limited disease.
  • However, recent exploratory studies indicate that low-dose methotrexate may represent an overall well tolerated therapy in a subset of patients with refractory early-stage CTCL, as may pegylated liposomal doxorubicin, which is currently being investigated in this specific clinical setting.
  • Another recently FDA-approved therapy is the interleukin-2 fusion toxin denileukin diftitox, which is now well established to play a role in the treatment of refractory CTCL, including early-stage extensive plaque disease.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Immunologic Factors / therapeutic use. Phototherapy / methods. Retinoids / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734503.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Retinoids
  • [Number-of-references] 93
  •  go-up   go-down


22. Gribben JG, Hallek M: Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol; 2009 Mar;144(6):818-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rediscovering alemtuzumab: current and emerging therapeutic roles.
  • The humanized anti-CD52 monoclonal antibody alemtuzumab belongs to the family of Campath-1 antibodies, which were initially developed for their ability to prevent graft-versus-host disease (GVHD) and graft rejection in stem cell transplantation.
  • Alemtuzumab is indicated for the treatment of chronic lymphocytic leukaemia (CLL) and has demonstrated considerable activity in relapsed/refractory disease and in previously untreated disease.
  • It has been shown to induce minimal residual disease-negative responses as a single agent or as part of consolidation therapy in a meaningful proportion of patients with CLL and has shown promising activity in patients with high-risk cytogenetic markers.
  • Alemtuzumab may also have significant activity in T-cell malignancies, such as mycosis fungoides and T-cell prolymphocytic leukaemia.
  • This article reviews our current understanding of alemtuzumab and discusses its emerging role in the treatment of CLL and other haematological malignancies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Graft vs Host Disease / prevention & control. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Stem Cell Transplantation. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183194.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 80
  •  go-up   go-down


23. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J: Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother; 2006 May;7(7):907-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bexarotene in the treatment of cutaneous T-cell lymphoma.
  • Mycosis fungoides and the leukaemic variant Sézary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.
  • No curative therapy exists and patients ultimately develop advanced or relapsed disease that is refractory to standard treatment options.
  • Therefore, there is a great need for the development of novel emerging therapies.
  • Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.
  • Bexarotene was found to induce apoptosis in a variety of preclinical in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-centre, open-label Phase II - III clinical trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to standard therapies.
  • New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-alpha, denileukin diftitox or phototherapy.
  • This article reviews the biological properties, pharmacokinetics, clinical efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634713.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


24. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ: Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol; 2000 Apr;27(2 Suppl 5):32-6
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
  • We have previously demonstrated that pentostatin (Nipent; SuperGen, San Ramon, CA) is highly effective in the treatment of hairy cell leukemia and report here the long-term outcome of this study.
  • Of the 25 patients who achieved a CR, 14 (56%) remain in CR at a median of 119 months (range, 109 to 133 months) from the time of CR.
  • Nine additional patients relapsed at a median time of 49 months (range, 15 to 122 months).
  • Only three of the relapsed patients have required treatment: two patients who received cladribine achieved CRs; the third received interferon-alpha and died from hairy cell leukemia.
  • Five patients have developed a second malignancy: one mycosis fungoides and four solid tumors.
  • There were no treatment-related deaths due to toxicity or opportunistic infection.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Canada. Cause of Death. Cladribine / therapeutic use. Female. Follow-Up Studies. Humans. Injections, Intravenous. Interferon-alpha / therapeutic use. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10877049.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine
  •  go-up   go-down


25. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F: Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol; 2001 Jan 15;19(2):398-405
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.
  • PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I.
  • Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient.
  • After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma.
  • For the 44 treated patients, progression-free survival (PFS; actuarial +/- SE) was 61% +/- 7% and survival was 58% +/- 9% at 12 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208831.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


26. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH Jr, Prinz BM, Guitart J: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol; 2005 Mar;141(3):305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate long-term outcomes, impact of maintenance therapy and potential curability of patients with mycosis fungoides (MF) treated with psoralen plus UV-A (PUVA) monotherapy.
  • Patients were stratified into relapse and nonrelapse groups based on whether their MF relapsed during study follow-up.
  • Baseline characteristics and treatment were compared between these groups.
  • RESULTS: Median follow-up time was 94 months (range, 5-242 months).
  • Those in the nonrelapse group received a higher cumulative dosage to CR (P = .03) and required longer treatment periods to achieve CR (P = .03).
  • One third of the patients developed signs of chronic photodamage and secondary cutaneous malignancies.
  • CONCLUSIONS: Psoralen UV-A is an effective treatment for MF, inducing long-term remissions and perhaps in some cases disease "cure."
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / pathology. PUVA Therapy / methods. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781671.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement